We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
Read MoreHide Full Article
Alkermes Plc (ALKS - Free Report) and partner Biogen Inc. (BIIB - Free Report) announced that the FDA has accepted for review the new drug application (NDA) for diroximel fumarate (BIIB098), the novel oral fumarate, which has been developed for the treatment of relapsing forms of multiple sclerosis (MS). The FDA has set an action date in the fourth quarter of 2019.If approved, Biogen and Alkermes plan to market diroximel fumarate under the brand name Vumerity.
The NDA was submitted in December 2018 and was supported by data from EVOLVE-1, a phase III study that evaluated long-term safety of diroximel fumarate in relapsing-remitting MS (RRMS) in about 700 patients. Further, Alkermes is also conducting the EVOLVE-MS-2 study, a five-week, head-to-head gastrointestinal (GI) tolerability study evaluating diroximel fumarate versus dimethyl fumarate.
Diroximel fumarate is designed to rapidly convert to monomethyl fumarate in the body and may have the potential to offer differentiated GI tolerability due to its chemical structure as compared to dimethyl fumarate.
MS is a crowded market, with many companies already having drugs in their portfolio approved for this indication. Biogen holds a strong position in the MS market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. Israel-based Teva Pharmceuticals (TEVA - Free Report) has long been in the MS market through its widely used drug Copaxone, which is facing stiff generic competition for the past few years.
Novartis’ (NVS - Free Report) MS portfolio comprises approved drugs like Gilenya and Extavia for the treatment of relapsing forms of MS.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
Alkermes Plc (ALKS - Free Report) and partner Biogen Inc. (BIIB - Free Report) announced that the FDA has accepted for review the new drug application (NDA) for diroximel fumarate (BIIB098), the novel oral fumarate, which has been developed for the treatment of relapsing forms of multiple sclerosis (MS). The FDA has set an action date in the fourth quarter of 2019.If approved, Biogen and Alkermes plan to market diroximel fumarate under the brand name Vumerity.
The NDA was submitted in December 2018 and was supported by data from EVOLVE-1, a phase III study that evaluated long-term safety of diroximel fumarate in relapsing-remitting MS (RRMS) in about 700 patients. Further, Alkermes is also conducting the EVOLVE-MS-2 study, a five-week, head-to-head gastrointestinal (GI) tolerability study evaluating diroximel fumarate versus dimethyl fumarate.
Diroximel fumarate is designed to rapidly convert to monomethyl fumarate in the body and may have the potential to offer differentiated GI tolerability due to its chemical structure as compared to dimethyl fumarate.
MS is a crowded market, with many companies already having drugs in their portfolio approved for this indication. Biogen holds a strong position in the MS market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. Israel-based Teva Pharmceuticals (TEVA - Free Report) has long been in the MS market through its widely used drug Copaxone, which is facing stiff generic competition for the past few years.
Novartis’ (NVS - Free Report) MS portfolio comprises approved drugs like Gilenya and Extavia for the treatment of relapsing forms of MS.
Zacks Rank
Alkermes currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>